Mahnaz Bayat | Neuropharmacology | Research Excellence Award

Published on by Top Pharmaceutical

Dr. Mahnaz Bayat | Neuropharmacology | Research Excellence Award

clinical neurology research center | Iran

Dr. Mahnaz Bayat is a dedicated and research-driven academic with extensive expertise spanning both experimental and clinical dimensions of neurological disorders. She currently serves as an Assistant Professor at the Clinical Neurology Research Center, where her work integrates translational neuroscience with patient-oriented clinical research. Dr. Bayat has substantial hands-on experience in clinical trials and advanced neurological investigations, with a particular emphasis on bridging laboratory discoveries and clinical application. Her scientific expertise includes disease modeling across a broad spectrum of neurological conditions, as well as sophisticated electrophysiological recording techniques that enable in-depth analysis of neural function and dysfunction. In parallel with her research activities, she is deeply engaged in graduate and postgraduate education, serving as a thesis advisor for neurology residents and supervising multiple Master’s and doctoral students in the basic medical sciences. Her academic teaching portfolio encompasses physiology education for students across medicine, dentistry, and pharmacy, reflecting her strong interdisciplinary foundation. Dr. Bayat has established a solid publication record in peer-reviewed scientific journals and is recognized for her meaningful contributions to collaborative and interdisciplinary research initiatives. Her primary research interests include electrophysiology, clinical neurology, neurodegenerative diseases, neurological biomarkers, and translational neuroscience, with a growing focus on improving diagnostic precision and therapeutic strategies. Through her combined roles as a clinician-scientist, educator, and researcher, Dr. Bayat continues to advance neurological science while contributing to the development of future clinicians and researchers in the field.

Citation Metrics (Scopus)

600

450

300

150

0

Citations
581

Documents
50

h-index
15

Citations
Documents
h-index


View Scopus Profile View Google Scholar Profile

Featured Publications

Slawomir Michalak | Neuropharmacology | Top Pharmaceutical Breakthrough Award

Published on by Top Pharmaceutical

Prof. Slawomir Michalak | Neuropharmacology | Top Pharmaceutical Breakthrough Award

Institute of Neurological Disorders Poznan University of Medical Sciences | Poland

Prof. Slawomir Michalak is an accomplished neurologist, neuropathologist, and laboratory medicine specialist whose contributions have significantly advanced clinical neuroscience, translational neurology, and biomarker-driven research. He leads the Stroke Unit at the University Hospital in Poznań while simultaneously heading the Department of Neurology, the Department of Neurosurgery, and the Institute of Neurological Disorders at Poznan University of Medical Sciences. His academic journey includes prestigious international fellowships at the Biochemisches Institut of Christian Albrechts Universität in Kiel and at the Istituto di Patologia Generale of the Università degli Studi in Perugia, where he strengthened his foundation in molecular neuropathology. He further enhanced his expertise through intensive neuropathology and laboratory medicine courses in leading European scientific hubs such as Berlin, Budapest, Lübeck, Aachen, and specialized mitochondrial research programs in Schroecken, Austria. As a visiting professor at the M. Ospanov West Kazakhstan State Medical Academy, he delivered advanced lectures and supervised doctoral research in neurodegenerative and demyelinating disorders.Prof. Michalak’s scientific portfolio demonstrates exceptional breadth and innovation. He has played a central role in multidisciplinary research initiatives, including a large Polish–Singaporean project developing computer-aided decision support systems for acute ischemic stroke therapy, and joint studies with international collaborators aimed at profiling pathological proteins in skin biopsies of patients with movement disorders. His work also encompasses biochemical and clinical signature identification for interferon therapy response in multiple sclerosis. As a contributor to the European COST Action project on mitochondrial mapping, he has examined the complex interplay of evolution, age, gender, lifestyle, and environmental factors on mitochondrial dynamics. His ongoing clinical research includes a major investigation on the influence of Cerebrolysin on blood–brain barrier integrity in acute ischemic stroke. He also collaborates with global experts on smart digital therapeutics using generative artificial intelligence and contributes to the Glioblastoma Research Group at Poznan University of Medical Sciences to advance biomarker-based early detection strategies.With more than five hundred scientific publications, a substantial cumulative impact factor, over two thousand citations, and a strong h-index, Prof. Michalak has established himself as a leading figure in contemporary neurology. His book publications, extensive consultancy roles, and active involvement in translational industry–academia partnerships further highlight his enduring impact. His research in stroke biology, neuroimmunology, neuro-oncology, and molecular biomarkers continues to shape clinical understanding and inspire innovation across the global neuroscience community.

Profile: Google Scholar

Featured Publications

Ambrosius, W., Michalak, S., & Kozubski, W., & Kalinowska, A. (n.d.). Myelin oligodendrocyte glycoprotein antibody-associated disease: Current insights into the disease pathophysiology, diagnosis and management. International Journal of Molecular Sciences, 22(1), 100.

Kazmierski, N. W. R., Michalak, S., & Wencel-Warot, A. (n.d.). Serum tight-junction proteins predict hemorrhagic transformation in ischemic stroke patients. Neurology, 79, 160.

Jasiak-Zatonska, M., Kalinowska-Łyszczarz, A., Michalak, S., & Kozubski, W. (n.d.). The immunology of neuromyelitis optica—Current knowledge, clinical implications, controversies and future perspectives. International Journal of Molecular Sciences, 17(3), 273.

Wyciszkiewicz, A., Kalinowska-Łyszczarz, A., Nowakowski, B., Kaźmierczak, K., & Michalak, S. (n.d.). Expression of small heat shock proteins in exosomes from patients with gynecologic cancers. Scientific Reports, 9(1), 9817.

Zaborowski, M. S., Spaczynski, M., & Nowak-Markwitz, E., & Michalak, S. (n.d.). Paraneoplastic neurological syndromes associated with ovarian tumors. Journal of Cancer Research and Clinical Oncology, 71.

Adamczak-Ratajczak, A., Kupsz, J., Owecki, M., Zielonka, D., Sowinska, A., & Michalak, S., et al. (n.d.). Circadian rhythms of melatonin and cortisol in manifest Huntington’s disease and in acute cortical ischemic stroke. Journal of Physiology and Pharmacology, 68(4), 539–546.

M. Imad Damaj | Neuropharmacology | Best Researcher Award

Published on by Top Pharmaceutical

M. Imad Damaj | Neuropharmacology | Best Researcher Award

Prof. Dr. M. Imad Damaj, Virginia Commonwealth University, United States

Prof. Dr. M. Imad Damaj is a distinguished pharmacologist specializing in pain, neuropathy, and drug dependence. A professor at Virginia Commonwealth University (VCU), he co-directs the Translational Research Initiative for Pain and Neuropathy. Holding a Ph.D. in Pharmacology from the University of Paris XI, he has made significant contributions to neuropharmacology and drug addiction research. An award-winning educator, he has received the VCU Award of Excellence and is a National Academy of Inventors inductee. His extensive work includes NIH study sections, journal editorial roles, and mentoring future scientists. 🌍📚🔬

Publication Profile

Scopus

Education

Prof. Dr. M. Imad Damaj 🎓 began his academic journey with a B.S. in Pharmacy from the University of St-Joseph (French Faculty of Medicine) in Beirut, Lebanon, in 1985. He then pursued an M.S. in Hospital Pharmacy (DESS) at the School of Pharmacy, University of Paris VI, France, in 1986. His passion for pharmacology led him to earn a Ph.D. in 1991 from the University of Paris XI, under the mentorship of Dr. Christian Jacquot. 🧪 His dissertation focused on the pharmacological and pharmacokinetic evaluation of COR3224, a novel antidepressant agent, in rats, contributing valuable insights to the field. 🧬

Experience 

Prof. Dr. M. Imad Damaj 🧪 has an extensive background in training and research. He began as a Hospital Pharmacist at the Pediatric Parenteral Nutrition Unit, Necker Pediatric Hospital, Paris (1985-1986) and later became a Pharmacy Resident at Ste-Anne Neuropsychiatric Hospital (1986-1987). His academic journey included a predoctoral fellowship at the University of Paris XI (1987-1991) and a postdoctoral fellowship at the Medical College of Virginia (1991-1993). 🎓 Since 1994, he has been actively involved in teaching at Virginia Commonwealth University, covering pharmacology, drug dependence, and pain control, mentoring students in pharmacy, dentistry, and medical sciences.

Awards

Prof. Dr. M. Imad Damaj 🎓 has received numerous prestigious awards and honors throughout his career. In 1990, he earned the SARGET Laboratories Award for his research on antidepressants in rat brains. He received postdoctoral travel awards from ASPET (1992) and CPDD (1993). Recognized as an Outstanding Young Investigator in 1995, he continued to receive accolades, including multiple NIDA Travel Awards (1996, 1999) and the College de France Award (2001). 🌟 At VCU, he was named Professor of the Year (2014) and won multiple teaching awards. In 2023, he was inducted into the National Academy of Inventors. 🏅

Professional Activity

Prof. Dr. M. Imad Damaj 🧪 has been actively engaged in professional activities, serving as an ad hoc reviewer for esteemed journals such as Journal of Pharmacology and Experimental Therapeutics, British Journal of Pharmacology, and Neurochemistry International. Since 1993, he has contributed as a judge for the Virginia Junior Academy of Sciences and Virginia Academy of Sciences. 🎓 He has also participated in educational outreach, including the Mini-Med School of Virginia. From 2002-2018, he was on the Editorial Advisory Board for JPET, and in 2021, he became Associate Editor for Frontiers in Pain Research.

Research Focus

Prof. Dr. Mohamad Imad Damaj is a distinguished researcher in neuropharmacology 🧠💊, with a strong focus on nicotinic acetylcholine receptors (nAChRs) 🔬 and their role in addiction, pain, and neuropsychiatric disorders. His work explores the mechanisms of nicotine addiction 🚬, opioid withdrawal ⚠️, and neuropathic pain 🔥, employing advanced mouse models 🐭 to investigate behavioral and molecular responses. He has contributed significantly to understanding novel pharmacological interventions 💉, including PPARα agonists and α7 nicotinic receptor modulators. His research has broad implications for pain management, substance use disorders, and neuroprotection.

Publication Top Notes

Characterization of a novel oronasal-restricted nicotine vaping self-administration model in mice

New PPARα Agonist A190-Loaded Microemulsion for Chemotherapy-Induced Peripheral Neuropathy

Sulfonium Moieties as Ammonium Bioisosteres: Novel Ligands for the Alpha7 Nicotinic Acetylcholine Receptor

Identification of ethanol analgesia quantitative trait loci and candidate genes in BXD recombinant inbred mouse lines

Upregulation of the neuropeptide receptor calcitonin receptor-like in the spinal cord via MLL2 in a mouse model of paclitaxel-induced peripheral neuropathy

Voluntary nicotine consumption and reward in a subset of diversity outbred founder strains

Activation of α7 nicotinic receptors attenuated hyperalgesia and anxiety induced by palatable obesogenic diet withdrawal

Proteomic analysis of dorsal root ganglia in a mouse model of paclitaxel-induced neuropathic pain

Characterization and validation of a spontaneous acute and protracted oxycodone withdrawal model in male and female mice

The potential effect of α7 nicotinic receptors modulation on palatable food-induced dependence-like behaviors